Healthcare Services

Stomach Cancer Market Outlook 2026–2030 with Key Growth Drivers

April 28, 2026April 28, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Is The Market Size Of The Stomach Cancer Market Expected To Scale Between 2026 And 2030?

The stomach cancer market size has experienced rapid expansion in recent years. It is anticipated to grow from $3.74 billion in 2025 to $4.26 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 13.9%. The growth observed in the historic period can be attributed to the rising incidence of gastric cancer globally, the prevalence of helicobacter pylori infections, the increasing use of chemotherapy as standard treatment, the expansion of hospital oncology infrastructure, and improvements in diagnostic imaging techniques.

The market for stomach cancer treatments is projected to experience substantial expansion over the upcoming years. This market is forecast to reach $7.14 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 13.8%. This anticipated growth is driven by factors such as the increasing embrace of precision oncology, heightened investment in innovative biologics, the broadening of immunotherapy development pipelines, a greater emphasis on detecting cancer at early stages, and enhanced availability of sophisticated cancer therapies. Key trends anticipated during this period encompass the wider utilization of targeted therapy protocols, the increasing application of combined immunotherapies, a concentrated effort on early diagnostic screening, the spread of customized treatment strategies, and improved incorporation of biomarker-guided testing.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=25913&type=smp

Which Strong Drivers Are Impacting The Stomach Cancer Market Growth?

The increasing occurrence of Helicobacter pylori infection is anticipated to fuel the expansion of the stomach cancer market going forward. Helicobacter pylori infection is a condition brought on by the Helicobacter pylori bacteria, which colonizes the stomach lining and can lead to inflammation, ulcers, and an elevated risk of stomach cancer. The surge in Helicobacter pylori infection cases is primarily due to inadequate sanitation, which facilitates the fecal-oral and oral-oral transmission of the bacteria in overcrowded or unhygienic living conditions. Helicobacter pylori infection promotes stomach cancer by causing chronic inflammation and cellular damage in the stomach lining, ultimately leading to precancerous changes and tumor development. For instance, in November 2024, data from the Government of Canada, a Canada-based government agency, revealed that the recurrence rate of Helicobacter pylori infection was 19% in 2023, with the rate varying based on factors such as geographic location and age group. Therefore, the growing prevalence of Helicobacter pylori infection is propelling the growth of the stomach cancer market.

What Are The Different Segment Types In The Stomach Cancer Market Segment Breakdown?

The stomach cancer market covered in this report is segmented –

1) By Type: Adenocarcinoma, Lymphoma, Gastrointestinal Stromal Tumor, Carcinoid Tumor, Other Types

2) By Therapy Type: Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy, Surgery

3) By Route Of Administration: Oral, Parenteral

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

5) By End-User: Ambulatory Surgery Centers, Hospitals And Specialty Clinics, Other End-Users

Subsegments:

1) By Adenocarcinoma: Intestinal Type, Diffuse Type

2) By Lymphoma: Mucosa-Associated Lymphoid Tissue Lymphoma, Diffuse Large B-Cell Lymphoma

3) By Gastrointestinal Stromal Tumor: Kit-Positive Gastrointestinal Stromal Tumor, Platelet-Derived Growth Factor Receptor Alpha-mutant Gastrointestinal Stromal, Wild-Type Gastrointestinal Stromal Tumors

4) By Carcinoid Tumor: Typical Carcinoid, Atypical Carcinoid

5) By Other Types: Squamous Cell Carcinoma, Small Cell Carcinoma, Undifferentiated Tumors

Which Trends Are Contributing To Changes In The Stomach Cancer Market?

Leading companies in the stomach cancer treatment market are concentrating on developing advanced solutions, such as claudin (CLDN18.2)-targeted cytolytic antibody therapy, to enhance the precision of first-line treatments for HER2-negative gastric and gastroesophageal junction (GEJ) adenocarcinoma. This claudin (CLDN18.2)-targeted cytolytic antibody therapy utilizes a monoclonal antibody designed to selectively bind to CLDN18.2-expressing tumor cells and induce cytotoxic effects when combined with chemotherapy, leading to improved progression-free and overall survival outcomes. For instance, in October 2024, Astellas Pharma US, Inc., a Japan-based pharmaceutical company, introduced Vyloy (zolbetuximab-clzb), a claudin (CLDN18.2)-directed cytolytic antibody for gastric and gastroesophageal junction (GEJ) cancer treatment. This innovative biologic therapy is administered intravenously alongside fluoropyrimidine- and platinum-containing chemotherapy, showing a median progression-free survival benefit of up to 10.6 months and overall survival of up to 18.2 months in clinical trials. This therapy precisely targets CLDN18.2-positive cancer cells, reducing off-target toxicity and increasing treatment specificity, marking a significant advancement in personalized oncology for advanced gastric cancer.

Who Are The Well-Known Companies In The Stomach Cancer Market?

Major companies operating in the stomach cancer market are Pfizer Inc., F. Hoffmann-La Roche Ltd, Merck And Co. Inc., Sanofi S.A., Bristol Myers Squibb Company, AstraZeneca plc, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly And Company, Amgen Inc, Daiichi Sankyo Company Limited, BeiGene Ltd., Celltrion Healthcare Co. Ltd., Biocon Limited, Zai Lab Limited, MacroGenics Inc., Astellas Pharma Inc., Ipsen Group, AbbVie Inc., Bayer AG, Ono Pharmaceutical Co. Ltd.

Get The Full Stomach Cancer Market Report:

https://www.thebusinessresearchcompany.com/report/stomach-cancer-global-market-report

Where Is The Stomach Cancer Market Most Concentrated Geographically?

North America was the largest region in the stomach cancer market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the stomach cancer market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Stomach Cancer Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/stomach-cancer-global-market-report

Browse Through More Reports Similar to the Global Stomach Cancer Market 2026, By The Business Research Company

Esophageal Cancer Market Report 2026

https://www.thebusinessresearchcompany.com/report/esophageal-cancer-global-market-report

Gastric Cancer Diagnostic Procedure Market Report

https://www.thebusinessresearchcompany.com/report/gastric-cancer-diagnostic-procedure-global-market-report

Tumor Ablation Market Report

https://www.thebusinessresearchcompany.com/report/tumor-ablation-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795